SNY and DNTH Related Headlines
Go Back- Guggenheim Defending Dianthus Therapeutics (DNTH): 'We reiterate our positive view'
- Raymond James on Dianthus Therapeutics (DNTH) Amid 15% Down Day: 'We See Overall Positive Readthrough to Claseprubart'
- TD Cowen Defending Dianthus Therapeutics (DNTH): 'We see weakness as a buying opportunity'

